Erudio Healtherudio.com
Sponsor
Regeneron Pharmaceuticals trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Regeneron Pharmaceuticals: LINKER-AL2. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 7 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Regeneron Pharmaceuticals). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LINKER-AL2 NCT06292780 · Regeneron Pharmaceuticals | relapsed or refractory systemic light chain amyloidosis | Phase 1/Phase 2 | 149 | 26 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| EMPOWER-Lung 1 NCT03088540 · Regeneron Pharmaceuticals DeepView → | first-line advanced NSCLC with PD-L1 expression ≥50% | Phase 3 | Deep | View | |||
| LINKER-MM1 NCT03761108 · Regeneron Pharmaceuticals DeepView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| EMPOWER-Lung 3 NCT03409614 · Regeneron Pharmaceuticals DeepView → | first-line advanced or metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| ELM-2 NCT03888105 · Regeneron Pharmaceuticals DeepView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 2 | Deep | View | |||
| LINKER-MM4 NCT05828511 · Regeneron Pharmaceuticals DeepView → | newly diagnosed multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| ELM-1 NCT02290951 · Regeneron Pharmaceuticals DeepView → | previously treated CD20-positive B-cell malignancies | Phase 1 | Deep | View | |||
| LINKER-MM3 NCT05730036 · Regeneron Pharmaceuticals StandardView → | relapsed/refractory multiple myeloma | Phase 3 | Standard | View | |||